Next-generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells.
Eris BameHao TangJeremy Carlos BurnsMillion ArefayeneKlaus MichelsenBin MaIsaac MarxRobin J PrinceAllie M RoachUrjana PoreciDouglas DonaldsonPatrick CullenFergal CaseyJing ZhuThomas M CarlileDipen SangurdekarBaohong ZhangPatrick TrapaJoseph SantoroParam MuraganAlex PellerinStephen RubinoDavide GianniBekim BajramiXiaomei PengAlex CoppellKatherine RiesterShibeshih BelachewDevangi MehtaMike PalteBrian T HopkinsMatthew ScaramozzaNathalie FranchimontMichael MingueneauPublished in: Clinical & translational immunology (2021)
Pharmacodynamic results obtained in preclinical and early clinical settings support the advancement of BIIB091 in phase 2 clinical trials.